No results found.
JD Foster, VMD, DACVIM, Friendship Hospital for Animals, Washington, DC
Sign in to Print/View PDF
This is a filled error message
To access full articles on www.cliniciansbrief.com, please sign in below.
Create an account for free
Want free access to the #1 publication for diagnostic and treatment information? Create a free account to read full articles and access web-exclusive content on cliniciansbrief.com.
Passwords do not match
Where are you from?
AG|Antigua and Barbuda
BA|Bosnia and Herzegovina
IO|British Indian Ocean Territory
CF|Central African Republic
CC|Cocos (Keeling) Islands
CD|Congo, the Democratic Republic of the
FK|Falkland Islands (Malvinas)
TF|French Southern Territories
HM|Heard Island and McDonald Islands
VA|Holy See (Vatican City State)
KR|Korea, Republic of
LY|Libyan Arab Jamahiriya
MK|Macedonia, the former Yugoslav Republic
FM|Micronesia, Federated States of
MD|Moldova, Republic of
MP|Northern Mariana Islands
PG|Papua New Guinea
KN|Saint Kitts and Nevis
VC|Saint Vincent and the Grenadines
ST|Sao Tome and Principe
GS|South Georgia and the South Sandwich Islands
PM|Saint Pierre and Miquelon
SJ|Svalbard and Jan Mayen
SY|Syrian Arab Republic
TW|Taiwan, Province of China
TZ|Tanzania, United Republic of
TT|Trinidad and Tobago
TC|Turks and Caicos Islands
AE|United Arab Emirates
UM|United States Minor Outlying Islands
VG|Virgin Islands, British
VI|Virgin Islands, U.S.
WF|Wallis and Futuna
DC|District of Columbia
Micronesia (Federated States Of)
US Minor Outlying Islands
Armed Forces Africa
Armed Forces Americas Aa (except Canada)
Armed Forces Canada
Armed Forces Europe Ae
Armed Forces Middle East Ae
Armed Forces Pacific Ap
PE|Prince Edward Island
Tell us about yourself
Choose the category that describes your business/professional activity
What best describes your position? (question 1 of 2)
Veterinarian Role: (question 2 of 2)
Non-Veterinarian Role: (question 2 of 2)
Yes, I would like to receive updates about products & services, promotions, special offers, news & events from Brief Media.
Already have an account? Sign in here.
Acceptance to the GDPR regulations is required.
Microbial culture and susceptibility testing is an integral part of the diagnosis and treatment of bacterial infections. The Clinical Laboratory Standards Institute (CLSI) evaluates the antibiotic concentration (ie, breakpoint) required to prevent growth of cultured bacteria, the drug’s pharmacokinetic properties, and the likelihood of clinical success for typical doses of the antibiotic to determine whether an isolate will be susceptible (S), intermediate (I), or resistant (R) to that particular drug. Cephalothin, a first-generation cephalosporin, has historically been evaluated to predict the susceptibility to all other oral drugs within that class (eg, cephalexin, cefadroxil, cephapirin). However, research has shown that cephalothin is poor at predicting cephalexin susceptibility. This limitation, combined with cephalexin’s position as the most commonly prescribed first-generation cephalosporin, highlights the need for cephalexin-specific CLSI guidelines.
Content continues after advertisement
This study evaluated bacterial isolates from a 4-year time span to determine minimum inhibitory concentration (MIC) breakpoints for 4 cephalosporins used in veterinary medicine (ie, cephalexin, cephalothin, cefovecin, cefpodoxime) and simulated the likelihood of successful eradication of the infection. The study results showed discrepancies in susceptibility between cephalothin and cephalexin. Most notable were the susceptibility results for the Staphylococcus pseudintermedius isolates that were positive for penicillin-binding protein 2A. Only 4.3% of these isolates had MIC values ≤2 µg/mL for cephalexin as compared with 66.3% for cephalothin. These results further confirm the poor agreement of cephalothin to predict cephalexin susceptibility, which has led the CLSI to replace cephalothin with cephalexin for testing canine isolates.
Key pearls to put into practice:
Microbiology laboratories should replace cephalothin with cephalexin on culture and susceptibility reports.
Cephalexin at 25 mg/kg PO q12h has a 90% likelihood of clinical success in dogs when treating isolates with a MIC ≤2 µg/mL. The likelihood of success for isolates with MICs of 4 µg/mL and 8 µg/mL is only 73% and 47%, respectively. Alternative drugs should be considered at these higher MICs based on culture and susceptibility report results.
If a bacterial isolate is resistant to oxacillin, it should also be considered resistant to all other β-lactam drugs, including cephalexin and cephalothin. Alternative drug classes should be used to treat such infections.
Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*
*2007-2017 PERQ and Essential Media Studies
It's Free & Simple
Delivered to Your Inbox
Join the Conversation
Follow us @CliniciansBrief
© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved.